Illumina, Inc. Strengthens Leadership Team with Key Appointments

In a strategic move to enhance its executive leadership, Illumina, Inc. (NASDAQ: ILMN) has announced the appointment of Michael Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer. These appointments, effective July 20, 2026, and August 3, 2026, respectively, reflect Illumina’s commitment to advancing its mission of improving human health through innovative genomic solutions.

Jacob Thaysen, CEO of Illumina, expressed enthusiasm about the new additions to the executive team, stating, "We are excited to welcome Mike and Julie to Illumina. Mike brings deep commercial expertise, a customer-first mindset, and significant experience scaling global organizations, while Julie is a highly accomplished legal and business leader with deep experience across the life sciences and medical technology sectors." Thaysen emphasized the importance of these appointments in supporting Illumina’s strategy to drive growth and deliver on its mission.

Michael Sullivan will take the reins as Chief Commercial Officer, where he will be responsible for leading Illumina's global commercial organization. With over 30 years of experience in commercial leadership across various sectors, including diagnostics, precision medicine, healthcare, and life sciences, Sullivan is poised to make a significant impact. His previous role as Chief Commercial Officer at Caris Life Sciences provided him with valuable insights into oncology diagnostics and precision medicine, equipping him with the skills necessary to drive growth and expand customer adoption at Illumina.

Before his tenure at Caris, Sullivan held senior commercial leadership roles at prominent companies such as Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott Diagnostics. His extensive background positions him well to lead Illumina through its next phase of growth.

Julie Coletti joins Illumina as the Chief Legal Officer, bringing with her a wealth of experience in legal, regulatory, and governance matters. In her new role, she will lead Illumina's global legal, regulatory, and government affairs teams and serve as corporate secretary to the Illumina Board of Directors. Her previous position as Chief Legal and Regulatory Officer at Align Technology has well-prepared her for the challenges she will face at Illumina.

Coletti's career is marked by significant legal leadership roles at Danaher Corporation and Bayer HealthCare, where she advised executive leaders and boards on complex issues ranging from compliance and intellectual property to governance and public policy. Additionally, her experience as a director for Fortis Life Sciences, a provider of solutions to life science and diagnostic companies, further enhances her capability to contribute to Illumina's strategic objectives.

With the addition of Michael Sullivan and Julie Coletti to the executive team, Illumina is poised to strengthen its position in the genomics market. Their combined expertise in commercial strategy and legal oversight will be instrumental as Illumina continues to innovate and expand its reach in various applications, including life sciences, oncology, reproductive health, and agriculture.

As the company embarks on this new chapter, stakeholders and investors alike will be watching closely to see how these leadership changes will impact Illumina's growth trajectory and commitment to improving human health globally.